The hematologic oncology sector is witnessing unprecedented transformation, with mantle cell lymphoma (MCL) emerging as a focal point for innovative therapeutic development. This rare but aggressive B-cell malignancy affects thousands of patients globally, creating substantial demand for effective treatment solutions. The evolving landscape of MCL therapeutics demonstrates...